![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, October 21, 2013 10:33:13 AM
http://www.fastcoexist.com/3020191/futurist-forum/your-future-energy-drink-will-blow-your-hair-back-with-stronger-caffeine-that...
The rise of questionably safe ultra-caffeinated food products has triggered the FDA in recent months to examine whether it really makes sense to stick the stimulant in "non-traditional" products like energy drinks and gum.
ChromaDex, a company that makes and licenses intellectual property for nature-identical ingredients (that is, natural ingredients which are produced synthetically), is on a mission to make sure that caffeine addicts still get their fix, even if the FDA decides to launch a dramatic crackdown.
It delivers 30% more caffeine into the blood, and is absorbed by the body at a 30% slower rate.
The company recently announced human clinical trial results for Purenergy, a caffeine-related ingredient that the company says delivers 30% more caffeine into the blood than traditional caffeine, is absorbed by the body at a 30% slower rate than regular caffeine (so it lasts longer), and cuts the half-life of caffeine by one quarter. Purenergy could, in other words, offer the same energy boost as traditional caffeine in significantly lower quantities, circumventing any future FDA caffeine limits for products.
For years, ChromaDex has been licensing IP for ingredients instead of developing them in-house. For instance, pTeroPure, a nature-identical version of trans-Pterostilbene--an ingredient found in blueberries that lowers blood pressure and has a calming effect--is found in up to 50 commercial products, including many dietary supplements.
But with Purenergy, Chromadex is getting into the market itself. The product is a caffeine and pTeroPure hybrid that--theoretically--nullifies caffeine's negative effects with the positive ones from pTeroPure. "pTeroPure is good for reducing blood pressure, and the negative side effects of caffeine are anxiety and hypertension related, so it cancels it out," claims ChromaDex CEO Frank Jaksch, Jr.
Supposedly co-crystallizing the two ingredients--bringing them together into one hydrogen-bonded whole--intensifies caffeine absorption and makes it last longer in the body. "The benefits of Purenergy come from the crystallization process," says Jaksch.
This kind of prolonged fix doesn't come cheap. Jaksch says that Purenergy will be a "premium-priced ingredient" compared to traditional caffeine. But if the FDA ever cracks down on caffeine, there may not be many options for energy product companies, except to find ways to do more with less caffeine. Non-caffeine alternatives that deliver a similar energy boost tend to be in a class of compounds called alkaloids (caffeine is an alkaloid; so is nicotine). But, says Jaksch, "The FDA stance is very clear: There's no chance in hell they're going to let a new alkaloid that's a stimulant onto the market unless someone brought in a huge battery of data."
ChromaDex is in the process of marketing Purenergy to companies now. Jaksch couldn't reveal any potential partnerships, but don't be surprised if Purenergy shows up in your Red Bull or Monster energy drink in the near future.
Recent CDXC News
- ChromaDex to Join Russell 2000® Index • Business Wire • 07/01/2024 12:32:00 PM
- Milestone Phase II Clinical Study Demonstrates Niagen®, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD) • Business Wire • 06/24/2024 12:32:00 PM
- ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC) • Business Wire • 06/13/2024 12:32:00 PM
- ChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT) • Business Wire • 06/07/2024 12:34:00 PM
- ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, June 11, 2024 • Business Wire • 06/04/2024 12:32:00 PM
- ChromaDex to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024 • Business Wire • 05/23/2024 12:34:00 PM
- ChromaDex’s Niagen® Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year Award • Business Wire • 05/22/2024 12:32:00 PM
- ChromaDex Corporation Reports First Quarter 2024 Financial Results • Business Wire • 05/08/2024 08:04:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:02:02 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:01:05 PM
- ChromaDex’s NIAGEN® (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar® Cellular Nutrition Cellular Energy Supplement • Business Wire • 04/30/2024 12:32:00 PM
- ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe® • Business Wire • 04/25/2024 12:34:00 PM
- ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024 • Business Wire • 04/24/2024 12:34:00 PM
- ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Market • Business Wire • 04/23/2024 12:32:00 PM
- ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program • Business Wire • 03/26/2024 12:32:00 PM
- ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results • Business Wire • 03/06/2024 09:04:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:02:29 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/06/2024 09:01:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/24/2024 02:00:40 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/24/2024 01:59:47 AM
- ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024 • Business Wire • 02/21/2024 01:32:00 PM
- ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024 • Business Wire • 02/05/2024 01:32:00 PM
- ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference • Business Wire • 01/26/2024 09:08:00 PM
- ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen® • Business Wire • 12/20/2023 02:04:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 09:00:16 PM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM